Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: Report of 30 cases;Intérêt des érythraphérèses à la phase initiale du traitement des hémochromatoses génétiques de type 1: Expérience à propos de 30 cas

Transfusion Clinique et Biologique

Volumn 18, Issue 5-6, 2011, Pages 553-558

  Poullin, P ^a   Lefevre P A ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

Author keywords

C282Y mutation; Erythrocytapheresis; Hereditary hemochromatosis; Iron overload; Red cell depletion

Indexed keywords

FERRITIN;

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CYTAPHERESIS; ERYTHROCYTAPHERESIS; ERYTHROCYTE; FEMALE; GENE MUTATION; HEMATOCRIT; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; IRON DEPLETION; MALE; PHLEBOTOMY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; CYTAPHERESIS; ERYTHROCYTES; FEMALE; FERRITINS; FLOW CYTOMETRY; HEMATOCRIT; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION, MISSENSE; PATIENT COMPLIANCE; POINT MUTATION; RETROSPECTIVE STUDIES;

EID: 82555169522     PISSN: 12467820     EISSN: 19538022     Source Type: Journal    
DOI: 10.1016/j.tracli.2011.04.004     Document Type: Article

References (13)

1. Niederau C., Fischer R., Purschel A., Stremmel W., Haussinger D., Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996, 110:1107-1119.
2. Barton J.C., McDonnell S.M., Adams P.C., Brissot P., Powell L.W., Edwards C.Q., et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998, 129:932-939.
3. Poullin P., Lefèvre P. Therapeutic erythrocytapheresis: technical aspects and clinical applications. Rev Med Interne 2008, 29:290-296.
4. Bolan C.D., Conry-Cantilena C., Mason G., Rouault T.A., Leitman S.F. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion 2001, 41:819-827.
5. McDonnell S.M., Grindon A.J., Preston B.L., Barton J.C., Edwards C.Q., Adams P.C. A survey of phlebotomy among persons with hemochromatosis. Transfusion 1999, 39:651-656.
6. Smith K.J., James D.S., Hunt W.C., McDonough W., Quintana R. A randomized, double-blind comparison of donor tolerance of 400mL, 200mL, and sham red cell donation. Transfusion 1996, 36:674-680.
7. Conte D., Mandelli C., Cesana M., Ferrini R., Marconi M., Bianchi A. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis. Report of 14 cases. Int J Artif Organs 1989, 12:59-62.
8. Kellner H., Zoller W.G. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis. Z Gastroenterol 1992, 30:779-783.
9. Muncunill J., Vaquer P., Galmes A., Obrador A., Parera M., Bargay J., et al. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apher 2002, 17:88-92.
10. Rombout-Sestrienkova E., van Noord P.A., van Deursen C.T., Sybesma B.J., Nillesen-Meertens A.E., Koek G.H. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study. Transfus Apher Sci 2007, 36:261-267.
11. Rombout-Sestrienkova E., van Noord P.A.H., Reuser E., Heeremans J., van Deursen C.T., Janssen M., et al. Therapeutic erythrocytapheresis (TE) versus phlebotomy [P] in the treatment of hereditary hemochromatosis (HH) patients: preliminary results from an ongoing randomized clinical trial. Transfus Apher Sci 2009, 40:135-136.
12. Meyer D., Bolgiano D.C., Sayers M., Price T., Benson D., Slichter S.J. Red cell collection by apheresis technology. Transfusion 1993, 33:819-824.
13. Woimant G, Tzincoca M, Boeri N, Rosencher N, Conseiller C. Tolérance et efficacité de l'érythraphérèse autologue en chirurgie orthopédique [abstract]. Communication au 8e congrès Société française d'hémaphérèse. Vichy, 20-22 octobre 1999.